2023-507959-29-00CompletedPhase 1
A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Aug 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 27 May 2024
- Start date
- 19 Jul 2024
- Lead sponsor
- Novartis Pharma AG
- EU CT number
- 2023-507959-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 6
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.